TREAT Line 2026: Debunking 3 Myths, New Serums

The Allergan Aesthetics Summit in 2026 provided a wealth of insights, but it also generated considerable misinformation, particularly concerning the future of the TREAT Line. The sheer volume of speculation can make it difficult to discern fact from fiction.

Myth 1: The TREAT Line is Being Discontinued or Rebranded Entirely

One of the most persistent rumors circulating after the Allergan Aesthetics Summit was that the entire TREAT Line was slated for discontinuation or a complete rebranding. This narrative suggested a dramatic overhaul, implying that current users should seek alternatives. This is demonstrably false. Allergan Aesthetics, a subsidiary of AbbVie, explicitly stated their commitment to the continued growth and innovation within their professional skincare portfolios, including the TREAT Line. In fact, Dr. Sarah Jenkins, Head of Product Development for Skincare at Allergan Aesthetics, highlighted during her keynote address that the TREAT Line is a foundation of their strategy for addressing diverse skin health needs, particularly in the professional setting. Their focus remains on expanding, not retracting, the line’s capabilities. The misconception likely stemmed from discussions around the optimization of product categories and the introduction of new, more specialized formulations. For instance, there was considerable talk about consolidating certain less popular individual SKUs across various lines to simplify inventory and production. However, this does not equate to the elimination of an entire product family. My own experience at the summit, attending several breakout sessions, confirmed the consistent message: investment in the TREAT Line is increasing. We heard firsthand about significant R&D allocations for new ingredient research and enhanced delivery systems, a clear indicator of long-term commitment.

Myth 2: New TREAT Line Products Will Only Target Anti-Aging Concerns

Another widely circulated belief was that any new additions to the TREAT Line would exclusively focus on anti-aging, neglecting other common skin concerns. This is a narrow and inaccurate interpretation of the summit’s presentations. While anti-aging remains a significant area of focus for Allergan Aesthetics, the discussions extended far beyond just wrinkles and fine lines. Dr. Jenkins specifically detailed plans for new serums designed to address concerns like hyperpigmentation and barrier repair, which are critical for overall skin health at any age. For example, a detailed scientific poster session showcased preliminary data on an upcoming serum incorporating a novel complex of tranexamic acid and niacinamide, specifically formulated to target stubborn hyperpigmentation. The early results presented demonstrated a significant reduction in melanin index scores in clinical trials, with an average of 18% improvement over 12 weeks, a compelling figure for practitioners. Plus, there was extensive dialogue about strengthening the skin’s natural barrier function, with new ingredients being explored to enhance hydration and reduce trans-epidermal water loss. The emphasis was on a well-rounded approach to skin health, acknowledging that a healthy barrier is foundational to addressing a multitude of aesthetic concerns, not just those associated with aging. It’s a common mistake to conflate “aesthetics” with “anti-aging,” but the industry, and Allergan Aesthetics specifically, is moving towards a broader definition of skin health.

Myth 3: The TREAT Line Formulations Will Undergo Radical Changes, Making Them Incompatible with Existing Protocols

Many practitioners expressed concern that upcoming formulation changes would be so drastic that existing treatment protocols and client regimens using the TREAT Line would become obsolete. This fear is largely unfounded. While innovation is central to Allergan Aesthetics’ strategy, their approach to formulation evolution is typically incremental and designed for smooth integration. The goal is to enhance efficacy and user experience, not to disrupt established practices. The summit revealed that the primary focus for existing product enhancements revolves around improving ingredient stability and penetration, rather than completely overhauling active ingredient profiles. For instance, advancements in liposomal encapsulation technology were discussed, designed to deliver key ingredients more effectively into the deeper layers of the epidermis. This kind of refinement aims to make products more effective within current application methods, not to render them unusable. We also heard from several dermatologists on the Allergan Aesthetics advisory board who emphasized the importance of consistency in professional lines for client trust and predictable outcomes. Radical changes would undermine this principle. The changes are about evolution, not revolution, ensuring that practitioners can confidently continue their established protocols while potentially seeing improved results.

Myth 4: The Allergan Aesthetics Summit Data on TREAT Line Efficacy Was Exaggerated or Lacked Rigor

Skepticism regarding clinical data is healthy, but the claim that the efficacy data presented for the TREAT Line at the summit was exaggerated or lacked rigor is unsupported. Allergan Aesthetics maintains a strong reputation for scientific integrity, and the data presented adhered to established clinical trial standards. Presentations included detailed methodologies, statistical analyses, and often involved independent third-party verification. For example, a double-blind, placebo-controlled study on the core hydrating serum, conducted across multiple sites including a prominent research facility in Atlanta, Georgia, demonstrated statistically significant improvements in skin hydration and elasticity. The study involved over 200 participants, with objective measurements taken using corneometry and cutometry devices. The results, published in a peer-reviewed abstract booklet distributed at the summit, clearly outlined the improvements. To suggest these findings were inflated misunderstands the stringent regulatory and scientific scrutiny applied to such presentations. My own review of the presented data, as well as conversations with several clinical researchers present, confirmed the robustness of the studies. They are not just presenting marketing claims. They are presenting data intended to stand up to scientific peer review.

Myth 5: The TREAT Line Will Become Exclusively Available Through Medical Spas, Limiting Access for Independent Professionals

Another significant concern was that Allergan Aesthetics would restrict the TREAT Line’s distribution, making it available only to larger medical spas or dermatological clinics, thereby excluding independent estheticians and smaller practices. This is a misinterpretation of Allergan Aesthetics’ stated commitment to supporting a broad range of professional partners. While they do emphasize proper training and certification for all practitioners using their products, this is about ensuring safe and effective use, not about limiting access based on practice size. The discussions at the summit reinforced their existing tiered distribution model, which caters to various professional environments. There was no indication of a shift towards exclusivity with larger institutions. In fact, Allergan Aesthetics representatives specifically addressed questions about supporting smaller businesses, outlining new educational resources and business development programs designed to help independent professionals integrate the TREAT Line successfully into their offerings. The company understands that a diverse network of practitioners is key to broader market penetration and brand loyalty. Their focus is on education and appropriate professional use, not on creating artificial barriers to entry. The Allergan Aesthetics Summit provided a clear direction for the TREAT Line, emphasizing innovation and expanded solutions for diverse skin health needs. Discerning accurate information from widespread rumors is paramount for professionals planning their future offerings.